

# Executive (dys)function after stroke: special considerations for behavioral pharmacology

Jessica M. Povroznik<sup>a,b,c</sup>, Jenny E. Ozga<sup>d</sup>, Cole V. Haar<sup>d</sup> and Elizabeth B. Engler-Chiurazzi<sup>a,b,c</sup>

Stroke is a worldwide leading cause of death and long-term disability with concurrent secondary consequences that are largely comprised of mood dysfunction, as well as sensory, motor, and cognitive deficits. This review focuses on the cognitive deficits associated with stroke specific to executive dysfunction (including decision making, working memory, and cognitive flexibility) in humans, nonhuman primates, and additional animal models. Further, we review some of the cellular and molecular underpinnings of the individual components of executive dysfunction and their neuroanatomical substrates after stroke, with an emphasis on the changes that occur during biogenic monoamine neurotransmission. We concentrate primarily on changes in the catecholaminergic (dopaminergic and noradrenergic) and serotonergic systems at the levels of neurotransmitter synthesis, distribution, reuptake, and degradation. We also discuss potential secondary stroke-related behavioral deficits (specifically, poststroke depression as well as drug-abuse potential and addiction) and their relationship with stroke-induced deficits in executive function, an especially

important consideration given that the average age of the human stroke population is decreasing. In the final sections, we address pharmacological considerations for the treatment of ischemia and the subsequent functional impairment, as well as current limitations in the field of stroke and executive function research. *Behavioural Pharmacology* 29:638–653 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

*Behavioural Pharmacology* 2018, 29:638–653

**Keywords:** cognitive flexibility, decision making, monoamine, stroke, working memory

<sup>a</sup>Center for Basic and Translational Stroke Research, <sup>b</sup>Department of Physiology, Pharmacology, and Neuroscience, <sup>c</sup>Rodent Behavior Core, Health Sciences Center and <sup>d</sup>Injury and Recovery Laboratory, Department of Psychology, West Virginia University, Morgantown, West Virginia, USA

Correspondence to Elizabeth B. Engler-Chiurazzi, PhD, Department of Physiology, Pharmacology, and Neuroscience, PO Box 9229, One Medical Center Drive, Morgantown, WV 26506-9229, USA  
E-mail: elengler@hsc.wvu.edu

Received 4 June 2018 Accepted as revised 21 August 2018

## Introduction

Afflicting nearly 795 000 people per year and associated with an annual cost of 34 billion dollars in the USA alone, stroke is the fifth leading cause of death and the leading cause of long-term disability (Benjamin *et al.*, 2017). Importantly, direct costs associated with stroke patients' medical care are expected to triple in the coming decades as the 'Baby Boomer' population ages (Lesniak *et al.*, 2008; Heidenreich *et al.*, 2011). The functional consequences of stroke can be diverse, and the success of medical recanalization interventions to re-establish blood flow and tissue oxygenation, such as chemical or mechanical endovascular therapy, are important predictors of outcome (Gurman *et al.*, 2015; Rangel-Castilla *et al.*, 2016). Currently, there is a paucity of pharmacological treatment options for stroke, despite many decades of research and many failed clinical trials of neuroprotective agents. The sole proven therapy for ischemic stroke is the thrombolytic agent, recombinant tissue plasminogen activator, which can only serve limited patient populations and has an exceptionally short therapeutic window of 4.5 h (Huang *et al.*, 2006) due to the unacceptable increased risk of cerebral hemorrhage when given after that time point. Despite reductions in

'door-to-needle' times in recent years, only a small fraction of stroke patients receive this intervention (Schwamm *et al.*, 2013). Taken together, the large numbers of affected patients, the devastating long-term consequences of the disease, and the lack of viable treatment options highlight a critical need to characterize the neuropathological cascades associated with stroke and to develop novel therapeutic interventions for the treatment of ischemia, its comorbidities, its secondary consequences and its long-term chronic symptoms.

Accounting for 87% of stroke cases, ischemic stroke is caused by blockage of a cerebral artery, resulting in a loss of blood flow to the brain area supplied by that artery; stroke due to other causes, such as intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH), account for 10 and 3% of cases, respectively (Benjamin *et al.*, 2017). Stroke represents a complex disease pathology that is profoundly influenced by a variety of factors including the ischemic or hemorrhagic nature of the stroke, localization of the infarct, as well as whether reperfusion was achieved and how quickly it took place following the insult (Bramlett and Dietrich, 2004). At the cellular level, ischemic stroke results in severe reductions

in cerebral blood flow at the ischemic site, depriving neurons of crucially needed oxygen and glucose, which results in the depletion of ATP reserves and an energy crisis in local brain tissues. Ionic disruption, metabolic stress, and cell death in this ischemic core are evident within hours of initial insult. Surrounding the necrotic core is the ischemic penumbra, in which tissues experience secondary impacts of stroke-induced pathological cascades affecting the core; this region represents an area at which therapeutic neuroprotective interventions can be directed. More broadly within the ischemic brain, stroke induces damage to white matter tracks, disruption of cerebrovascular integrity, and initiation of inflammatory pathways, resulting in a series of long-term secondary brain injuries and numerous behavioral deficits. Generally, available interventions only target one facet of the heterogeneous injury cascade, indicating a need to explore additional avenues for novel therapeutic targets that can affect multiple injury mechanisms and pathological cellular cascades, and ultimately ameliorate chronic symptomatology to improve functional recovery.

### Stroke models

In order to adequately study the pathophysiology of stroke, as well as the effects of potential neuroprotective agents, selection of the appropriate animal model is necessary. Models of cerebral infarct have been assessed in a variety of species, including but not limited to rodents, rabbits, pigs, sheep, dogs, and nonhuman primates (NHP) [for reviews, see Bacigaluppi *et al.* (2010); Tajiri *et al.* (2013)]. For the purposes of this review, we will focus on the strengths and limitations of rodent and NHP animal models in experimental stroke research.

As described in the previous section, strokes can be broadly defined as either ischemic (a vessel blockage) or hemorrhagic (a vessel bleed), with cerebral ischemia being further dichotomized into focal (in which a singular vessel is occluded) and global (in which there is an overall lack of oxygen and nutrient substrates to meet the energy demands of the brain) subtypes. Both ischemic and hemorrhagic stroke have the capacity to impact different brain regions (e.g. cortical regions such as the frontal and temporal lobes, and subcortical regions such as the striatum, cerebellum, and brain stem, etc.) as well as different sections of prominent cerebral vasculature. Because of this inherent variability, factors such as lesion/infarct size and location, as well as cerebral blood flow, and sympathetic innervation leakage will also vary among stroke types. As such, various animal models have been developed to address the anatomical and physiological differences and their subsequent pathophysiological manifestations (Howells *et al.*, 2010; Yan *et al.*, 2015). In addition to the development of different types of stroke models, another factor to consider is variation within individual models. For example, certain types of stroke inductions can be either permanent or transient, with

permanent models translating to an irreversible blockage of a vessel, and transient models allowing for the reversal of the blocked vessel by a procedure termed recanalization in which the occluded vessel is reopened, often (but not always) followed by reperfusion, or the restoration of cerebral blood flow to the occluded site (Wells *et al.*, 2012). As well, different techniques can exist to achieve the same parameters of a given model (Tamura *et al.*, 1979; Engel *et al.*, 2011), as we will discuss in this section.

The most common type of animal stroke model is that of focal ischemia. One approach to induce this pathology is through mechanical or non-mechanical middle cerebral artery (MCA) occlusion (MCAO). Mechanical MCAO can be achieved through the use of intraluminal filaments or ligation sutures, surgical clips, or cauterization of the vessel through electrocoagulation (Tamura *et al.*, 1979; Tyson *et al.*, 1984; Howells *et al.*, 2010; Engel *et al.*, 2011; Yan *et al.*, 2015). Some mechanical MCAO techniques, particularly the filament and ligation variations, can both be completed with (through either craniotomy or craniectomy) or without opening the skull (Longa *et al.*, 1989; Agarwalla *et al.*, 2014). Advantages of avoiding opening the skull include bypassing surgically induced damage to the surrounding dura and cranial bone structures, as well as the possibility of cerebral spinal fluid (CSF) leakage. Moreover, standard MCAO models are often highly successful in stroke induction when performed by a skilled surgeon, with fairly low mortality rates (~10%) (Wang *et al.*, 2017), and can be achieved in several other species in addition to rodents and NHPs (Howells *et al.*, 2010; Yan *et al.*, 2015). However, some known disadvantages of mechanical MCAO include high variability of lesion/infarct volume and an inability to assess thromboembolism, a characteristic of stroke pathophysiology commonly found in the human population (Howells *et al.*, 2010). Furthermore, in MCAO models in which a craniotomy or craniectomy is not performed, but rather occlusion of the MCA is achieved by ligation through an incision made into the neck, there is the added concern of an induced proinflammatory response, as a result of the surgical incision (in addition to the known, stroke-induced immune response), which may impact infarct pathophysiology, and as such, is not representative of human stroke. Moreover, non-mechanical techniques also exist for MCAO models and are primarily thromboembolic in nature, and have the advantage over mechanical MCAO models in that they more closely model human stroke. In brief, the traditional thrombotic model is accomplished through the injection of a clot-forming agent into the blood circulation near the MCA (Chen *et al.*, 2015). Although the photothrombotic model incorporates the injection of a photosensitive dye to chemically induce thrombosis in a non-invasive manner (Watson *et al.*, 1985), other approaches can also be used to induce focal ischemia in rodents and NHPs. For example, a model that incorporates the

injection of endothelin-1, a potent vasoconstrictor, and another model that implements the insertion and inflation of a catheter-guided balloon near the MCA, both achieve focal ischemia (Virley *et al.*, 2004; Gao *et al.*, 2006).

Applied less extensively in experimental stroke research are models of global ischemia. These models usually consist of quantifiable variations of vessel occlusion (VO). As such, the 2-VO, 3-VO, and 4-VO models are achieved through ligation of different combinations of the carotid, vertebral, and basilar arteries (Traystman, 2003; Cechetti *et al.*, 2010; Yang *et al.*, 2014). Induction of controlled cardiac arrest and subsequent resuscitation has also been implemented as a model of global ischemia (Kawai *et al.*, 1991).

Although the majority of cerebral strokes are focal ischemia, researchers can also model hemorrhagic phenotypes. More specifically, two prominent subtypes of hemorrhagic stroke exist: ICH and SAH. ICH occurs when weakened blood vessels rupture and leak into brain parenchyma. Common models of ICH include collagenase injection and balloon insertion and inflation (Sinar *et al.*, 1987; MacLellan *et al.*, 2010). Moreover, transgenic modification of rodent models has been used to create hypertensive mice that are highly susceptible to ICH with supplementation of a high-sodium diet (Alharbi *et al.*, 2016); however, this model is not as easily accessible in NHPs, as it is in rodents, as transgenic modification among NHPs raises extreme ethical, technical, and financial concerns. SAH occurs when ruptured blood vessels bleed ‘around’ the brain, into the subarachnoid space, rather than ‘into’ the brain as with ICH. Although less common in the human population than ICH, SAH models have also been validated across multiple animal species (Marbacher, 2016). A fairly reproducible model of SAH is performed through autologous blood injection; in this model, the blood is injected into the cisterna magna, a prominent opening within the subarachnoid space (Mori, 2014). Another common approach for SAH induction involves endovascular puncture of a subarachnoid vessel (Kooijman *et al.*, 2014). An advantage of the endovascular puncture model over the autologous blood injection model, is that the mechanical and physiological damage surrounding the vessel injury can be easily studied and assessed.

In addition to examining the differences and similarities, as well as advantages and disadvantages among different models from a technical perspective, it is also critical to consider the species to which a stroke induction model will be applied. A vast array of advantages and disadvantages exist between small animal models, such as rodents, and larger animal models, such as NHPs (Cook and Tymianski, 2012). For instance, advantages of rodent models over NHPs include an easier rate of replicability, lower variability of lesion size, an easier conduit for the implementation of genetic manipulation and

intervention, an easier means of care, and a lower cost burden (Cai and Wang, 2016). In contrast, broad physiological, immunological, and behavioral differences between rodents and NHPs exist, with NHPs proving much more analogous to humans than rodents (Mestas and Hughes, 2004; Jickling and Sharp, 2015; Phillips *et al.*, 2015; Cai and Wang, 2016; Fan *et al.*, 2017). Similarly, various aspects of brain anatomy, including cerebral volume, white matter-to-gray matter proportion, cerebral vasculature, and whole brain complexity (a more complex, gyrencephalic NHP brain compared with a lissencephalic rodent brain) also demonstrate the advantage of using an NHP model over a rodent model (Cai and Wang, 2016; Fan *et al.*, 2017). Moreover, with NHPs having more anatomically similar brain regions to humans than rodents, it is easier to map on the functions and behavioral outcomes of a more developed, NHP prefrontal cortex (PFC), the brain region responsible for executive functioning, to the human PFC. Taken together, these anatomical similarities between humans and NHPs are intricately linked to their functional outputs and, as such, could allow for a much stronger assessment of executive function in the human stroke population.

### Stroke and executive dysfunction

One area of deficit that has the potential to exert profoundly negative impacts to quality of life among stroke survivors is that of executive function. Below, we review executive-function deficits following stroke in humans, NHP, and additional animal models. Further, we review some of the cellular and molecular underpinnings of the individual components of executive dysfunction after stroke, with an emphasis on the changes that occur in biogenic monoamine transmission due to the importance of this system in executive functioning [for reviews, see Arnsten and Li (2005); Robbins and Arnsten (2009); Logue and Gould (2014)], particularly changes in the catecholaminergic [dopaminergic and norepinephrine (NE)] and serotonergic systems. It is worth noting that, currently, there is insufficient literature evaluating the changes of various endogenous monoamine neurotransmitter systems during executive dysfunction in the context of stroke. Rather, the literature is divided into three bodies: one that focuses predominantly on monoamine neurotransmission modulation during executive function/dysfunction, one that addresses executive dysfunction associated with stroke, and one that emphasizes monoamine neurotransmission disruption following stroke. Thus, we draw from multiple bodies of primary literature in an attempt to bridge the gaps between these three bodies of literature, thereby more precisely elucidating potential therapeutic avenues for the treatment of monoamine neurotransmission-induced executive dysfunction in the stroke population.

Secondary consequences of stroke are largely comprised of mood dysfunction, as well as sensory, motor, and

cognitive deficits. This section of the review will focus on the cognitive deficits associated with stroke, specifically those associated with executive dysfunction that frequently afflict poststroke patients. Executive dysfunction occurs in as much as 75% of stroke patients and poses a critical problem for the quality of life of these individuals (Riepe *et al.*, 2004; Zinn *et al.*, 2007; Lesniak *et al.*, 2008). From both a human and nonhuman perspective, we can model executive function as an assemblage of multiple components primarily comprised of the following cognitive processes: inhibitory control, which is closely related to impulsivity, the ability to plan and make decisions, working memory, and cognitive flexibility, which is associated with mental speed processing, problem solving/error processing, and attentional control (Diamond, 2013); these processes are largely carried out in the PFC of the mammalian brain (Squire *et al.*, 2013). However, it is important to note that many of these components are not necessarily independent, often working in concert with one another to accomplish top-down, goal-driven tasks (e.g. maintaining attention control, and therefore utilizing the inhibitory response to block irrelevant stimuli, is necessary for intact working memory during problem solving and reasoning tasks), as we will address below. Further, within both preclinical and clinical settings, executive function can be assessed either through laboratory-based or naturalistic/real-world situations (Chan *et al.*, 2008). Among the stroke population, it is common for one or more neurotransmitter systems to be altered as a downstream result of the ischemic or hemorrhagic insult (Wurtman and Zervas, 1974; Weinberger and Nieves-Rosa, 1988; Kanthan *et al.*, 1996), potentially leading to poor long-term cognitive outcomes in which patients struggle with high-level intellectual functioning and additional behavioral sequela [e.g. drug-abuse potential or drug-seeking behavior, an area in which evidence is currently lacking and in further need of research, as well as poststroke depression (PSD)], which will be discussed later in this review.

#### **Impulsivity (decision-making/risk-taking/planning/inhibitory control)**

Decision-oriented impulsivity is defined as a behavioral response that is often the result of rapid decision making with little to no premeditated consideration of the consequences that may arise from the decision or behavior and is generally mediated by the medial orbitofrontal cortex in humans (Bechara *et al.*, 2000a). The impulsivity construct can also be motor-oriented. Indeed, motor impulsivity is generally described as a failure to implement the inhibition control response (Roharikova, 2016) and is maintained primarily by the fronto-basal-ganglia network (Chamberlain and Sahakian, 2007). Individuals displaying impulsive tendencies struggle with the ability to plan and lack inhibitory control, often leading to risky decision-making in potentially harmful situations [reviewed by Jurado and Rosselli (2007)]. In humans,

multiple studies have documented that poststroke individuals often struggle with impulsivity and decision making (Binder, 1984; Bechara *et al.*, 2000b; Poulin *et al.*, 2013). For example, Scheffer *et al.* (2016) used the Go/No-Go motor impulsivity task to show that patients with right frontal-lobe stroke performed worse than the control group. In the Go/No-Go task, an individual is asked to perform a specific action in response to a specific stimulus (Go) and to inhibit that same action in response to a different stimulus (No-Go) (Gomez *et al.*, 2007). Cardoso *et al.* (2014) implemented the Iowa Gambling Task as a measure of both risky decision making and impulsivity to frontal lobe and cerebellar lobe stroke patients and healthy controls. During the Iowa Gambling Task, participants must choose cards from decks that are either associated with a 'reward' or a 'penalty'. Individuals with inhibitory control and decision-making deficits will often impulsively choose cards that are associated with a penalty even after a reward versus penalty distribution pattern has been established (Buelow and Suhr, 2009). Both stroke groups performed poorly relative to the healthy participants, and, when compared with each other, the two stroke groups did not significantly differ in their performances (Cardoso *et al.*, 2014), suggesting that the PFC is not the only region responsible for governing executive function, at least in the context of stroke.

#### **Working memory**

Working memory is an active form of short-term memory that is able to be manipulated via attention shifting, blocking of external, irrelevant stimuli, and updating of the contents being held in the working memory in order to achieve problem solving tasks (Squire *et al.*, 2013) and is processed primarily within the dorsolateral PFC (Levy and Goldman-Rakic, 2000). Working memory typically lasts within the broad range of a few seconds to several hours, and can be categorized into two primary subtypes – verbal and spatial – both of which can be assessed through stimulus-specific behavioral tasks. Like most components of executive functions, an intact working memory involves the utilization of other functional components. For example, a deficit in working memory would likely impede one's ability to plan, as the individual would display difficulty in retaining the relevant information for an abbreviated time window. Moreover, certain behavioral measures of impulsivity are associated with working memory deficits in rodent models (James *et al.*, 2007).

Human studies have indicated working memory deficits in the stroke population. For example, van Geldorp *et al.* (2013) used a computerized delayed-match-to-sample task in which participants were shown either spatial, object, or binding (spatial + object) cues and then had to remember which cue was presented after a brief temporal delay. Relative to controls, stroke patients showed

working memory deficits on both spatial and object-based components of the task, but not the binding component, suggesting that different neuroanatomical regions are implicated in the subdimensions of working memory. Further, Roussel *et al.* (2012) investigated the impact of stroke on both the visuospatial and verbal components of working memory. In their study, stroke patients were assessed on phonological loop (verbal working memory), visuospatial sketchpad (visuospatial working memory), and central executive (the 'master' integrator between the two subsystems). The results indicated mild working memory impairment in stroke patients with frontal lobe lesions, with an emphasis on the rehearsal process aspect of the phonological loop component of verbal assessments, and less discernible deficits in the spatial components of the working memory-based tasks. Roussel *et al.* (2012) attributed these discrepant findings to regional differences in patients with frontal versus posterior lesions.

In alignment with the association between the cerebellar region and impulsivity-based tasks (Cardoso *et al.*, 2014), this region has also been implicated during working memory procedures. As such, functional MRI studies have shown the importance of the cerebellum, specifically the corticocerebellar circuitry, for intact working memory. Specifically, Ziemus *et al.* (2007) used functional MRI during a computerized two-back working memory assessment, in which participants had to remember a specific sequence of presented letters on a computer screen in such a way that whenever the current letter presented was the same as the letter presented the one before the last (or 'two-back'), they made a response. Results demonstrated that stroke patients with cerebellar lesions had increased activation in posterior and cerebellar regions relative to healthy controls, who had activations in all regions of the corticocerebellar circuitry; this suggested a possible compensatory mechanism among stroke patients in which the cerebellum was utilized during the working memory task.

In addition to evidence from human studies, researchers have demonstrated the impact of ischemic infarct on memory using murine models. Specifically, Zhou *et al.* (2016) implemented a photothrombosis model of focal stroke in the PFC, such that poststroke regional connectivity and certain behavioral outcomes (i.e. working memory) could be assessed. Poststroke, mice were tested on an object location recognition task, in which the animals were allowed to explore two identical objects in an empty arena. After a delay interval, one of the original two objects was moved to a new location relative to the animal. Object preference was used as the primary dependent variable, as mice with intact memory can discriminate the novel location better than mice with memory deficits (Dix and Aggleton, 1999; Vogel-Ciernia and Wood, 2014). Both the stroke and sham mice were able to discriminate the novel location at 1 week after the

stroke, but only sham mice were able to discriminate novelty 4 weeks after the stroke, indicating a delayed-onset spatial memory deficit in PFC stroke mice (Zhou *et al.*, 2016).

### **Cognitive flexibility (speed and error processing/attention)**

Cognitive flexibility is defined as an ability to shift or update mental processes depending on changing stimuli in the environment, and is processed predominately in the ventrolateral PFC (Verdejo-Garcia *et al.*, 2015). Like most other components of executive function, this component relies heavily on the simultaneous interplay of various other processes, such as attentional control, speed and error processing, working memory, and inhibitory control [for review, see Diamond (2013)]. For example, the ability to teach or learn a new concept using different methods involves the utilization of different thought perspectives by the inhibition of one perspective and the adaptation of a new perspective, a cornerstone of cognitive flexibility. Furthermore, cognitive flexibility is essential for higher-level executive functioning such as problem solving, reasoning, and abstract thinking, and is thus seen as a crucial component to fluid intelligence (Ionescu, 2012; Dajani and Uddin, 2015).

Deficits in attentional control, or 'set-shifting', can be seen after the stroke through the implementation of the Wisconsin Card Sorting Test (WCST), a test that requires participants to match or classify cards on the basis of instructions given by the experimenter (i.e. match the cards according to number, color, shape, etc.). Once participants establish a correct pattern of matching, they are reinforced only when they adapt a new matching strategy, thus shifting them from one processing strategy to another (Mountain, Snow, 1993; Nyhus and Barcelo, 2009). Neurologically healthy individuals with no PFC impairment should be able to shift and update card-matching strategies fairly easily, while those with attentional control deficits will likely be unable to adjust their cognitive strategy and will instead persevere on the original method. Su *et al.* (2008) implemented a variation of the WCST (WCST-64) with stroke patients and found that it was a sensitive assessment for detecting deficits in cognitive flexibility in such a population. However, other researchers have disagreed (Jodzio and Biechowska, 2010) due to the lack of executive function-related factors assessed and therefore the overly broad evaluation, resulting in some discrepancy in the field. Taken together, the conflicting reports of the validity of the WCST among the stroke population should warrant caution among clinicians when choosing the appropriate tools for poststroke assessment.

Given that the thalamic and subthalamic regions have neuronal projections to the frontal lobe (Cardoso *et al.*, 2014), a study by Cordova *et al.* (2014) addressed the impact of rodent stroke-induced thalamic and medial

PFC infarcts on an attentional set-shifting task. Rats were trained to find a buried food reward before task administration. During the first day of the task, rats were rewarded for responding to a stimulus associated with one of the possible locations of the buried reward. On subsequent days, rats had to discriminate between relevant and irrelevant stimuli associated with the food reward, followed by new locations of buried food associated with a new stimulus; this required the rats to shift their attention from a previously learned association between stimulus and food reward to a new association for a rewarding stimulus. Rats with medial PFC-based strokes performed worse than their thalamic-based stroke and control counterparts. Moreover, no deficits in attentional set-shifting in thalamic-lesioned rats were observed, thus emphasizing the importance of stroke region specificity in executive dysfunction.

In addition to the importance of regional specificity, age may be a vital factor in determining deficits in poststroke cognitive flexibility. Indeed, it is known that general age-related processes have negative impacts on cognitive flexibility; however, this effect could be potentiated by additional poststroke pathophysiology. Furthermore, although there are broad similarities among the pathophysiological processes of stroke-induced brain injury in varying ages of stroke populations, age-related differences still exist. As such, Cipolotti *et al.* (2015) reported cognitive differences related to aging among stroke patients in terms of the Stroop test of attention control, speed, and error processing. For the Stroop test, individuals must read a word aloud, often a color name, which is printed in a contrasting color (i.e. reading the word 'green' with all of the letters in the word green being printed in the color red) (Jensen and Rohwer, 1966; Scarpina and Tagini, 2017). Cipolotti *et al.* (2015) determined that age exacerbated executive dysfunction among stroke patients, suggesting that deficits in cognitive flexibility following stroke are likely due to a multitude of variables, including age.

### **Monoamine neurotransmission disruption following stroke**

Decision-making, working memory, and cognitive flexibility are associated with modulation of the monoamines – dopamine (DA), NE, and serotonin (5-HT). DA, is synthesized primarily in the substantia nigra and ventral tegmental areas, with clearly defined corticolimbic pathways implicated in its neurotransmission (Squire *et al.*, 2013). 5-HT is produced in the raphe nuclei of the brain stem and is transported through extensive pathways before exerting its cognitive effects within the PFC (Squire *et al.*, 2013). NE is synthesized in the brainstem locus coeruleus and exchanges information with the PFC by well-established corticocerebellar connections (Campbell *et al.*, 2008; Paterson *et al.*, 2012; Squire *et al.*, 2013). Biogenic monoaminergic disruption is a consequence of ischemic and

hemorrhagic strokes (Wurtman and Zervas, 1974; Weinberger and Nieves-Rosa, 1988; Kanthan *et al.*, 1996), leading to deficits in various executive-function components. Further, the disruptions due to brain insult in both subcortical and cortical regions result in attenuated neurotransmission of the various monoamine projections to the PFC, where they exert their primary influence, as well as excitotoxicity. As such, upon ischemic or hemorrhagic cerebral insult, the 'leaking' of these monoaminergic neurons and axons into the extracellular spaces consequently exacerbates the pathophysiological changes caused by the initial insult, leading to further death of surrounding neurons. Below, we will address the different mechanisms during monoaminergic signaling processes by which neurotransmission can be impacted following stroke.

### **Biosynthesis enzymes and monoamine precursors**

Monoaminergic precursors and the biosynthesis enzymes with which they interact in order to synthesize and secrete neurotransmitters are crucial to normal neuronal functioning. Here, we will address these precursors and related enzymes for the catecholaminergic and serotonergic systems. Tyrosine hydroxylase (TH) is the biosynthesis enzyme responsible for the conversion of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), the direct precursor of DA. Stroke literature has suggested that TH plays an important role in the disease pathophysiology. As such, Huh *et al.* (2003) demonstrated a link between transient changes in dopaminergic, TH-positive neurons and microglial activation in a rat stroke model, wherein a marked reduction of TH-positive dopaminergic cells was observed in the substantia nigra pars compacta 7 days after the insult, but only on the lesioned side of the brain; this effect was associated with a biphasic microglia activation response. A similar trend of reduced TH-positive dopaminergic cells within the ipsilateral side relative to the contralateral side 7–14 days after the stroke was observed in a previous study by Soriano *et al.* (1997).

Dopamine  $\beta$  hydroxylase (DBH) is a membrane-bound biosynthesis enzyme responsible for the conversion of DA to NE and has been utilized as both a biomarker and target for pharmacological manipulation within the catecholaminergic systems (Kaufman and Friedman, 1965; Rush and Geffen, 1980). Upon ischemic or hemorrhagic insult, NE levels within the PFC drastically decrease as noradrenaline leaks from neurons into the surrounding vasculature. This consequent reduction in brain NE can be translated to increased DBH in the peripheral blood serum, as blood–brain barrier (BBB) permeability increases after stroke (EIAli *et al.*, 2011; Merali *et al.*, 2017), and could possibly be the result of a compensatory measure. As such, Kanda *et al.* (1979) first demonstrated this poststroke consequence when they sampled serum DBH in stroke patients at multiple timepoints after the initial insult, finding the highest levels of DBH

immediately after stroke, with the values gradually declining in a time-dependent manner.

More recently, another study examined the levels of tryptophan (5-HT precursor), tyrosine (DA/NE precursor), and their metabolites among stroke patients. Ormstad *et al.* (2013), found decreased plasma levels of the monoamine precursors in stroke patients relative to healthy controls. This decrease in monoamine biomarkers relative to the increase in DBH shown by Kanda *et al.* (1979) could possibly be attributed to differences in blood collection timepoints utilized. Ormstad and colleagues attributed reduced levels of monoamine precursors to increased oxidation of tryptophan and tyrosine in the stroke group, a finding that supports the notion of an increased release of reactive oxygen species during the acute phase of the poststroke signaling cascade (Crack and Taylor, 2005; Olmez and Ozyurt, 2012).

### Neurotransmitters, receptors, and transporters

Depending on the location and severity of the infarct, changes in certain neurotransmitter levels occur at various time-points following the initial ischemic insult. These time-dependent changes affect monoamine receptor-binding and transporter-binding densities and, consequently, neurotransmission and cognition (Weinberger and Nieves-Rosa, 1988; Brouns *et al.*, 2010). For example, a study by Tsukada *et al.* (2004) revealed changes in both DA and 5-HT levels and receptor binding in a monkey stroke model. Specifically, PET and microdialysis techniques revealed hyperactivation of the cyclic adenosine 3',5'-monophosphate second messenger system, through modulation of specific 5-HT<sub>1A</sub> and DAergic receptor systems after experimental stroke in NHP. Upon further probing of these systems, radioligand binding and PET analyses revealed decreased D1 and 5-HT<sub>1A</sub> receptor binding 7 days after the insult. Microdialysis showed transiently increased striatal DA levels during both the occlusion and reperfusion phases of ischemia; in contrast, 5-HT levels increased transiently only after reperfusion had occurred (Tsukada *et al.*, 2004). Taken together, these findings indicate that cyclic adenosine 3',5'-monophosphate activation modulated by specific DA and 5-HT receptor systems could contribute to monoaminergic neuronal death after a stroke.

The dopamine transporter (DAT) has also been implicated in poststroke monoamine alterations. A study by Momosaki *et al.* (2016) assessed both DA receptor and transporter expression in the rat brain following mild ischemia. Results showed time-dependent expression of receptor and transporter levels that corresponded to a presence or absence of circling behavior, a specific type of poststroke locomotor behavioral deficit in which the animal is unable to walk in a straight line and will often walk in a circular pattern. Specifically, PET and radioligand-binding analysis revealed a transient increase in DAT at 2 days after the stroke, with decreased

receptor-binding levels observed at 7–14 days after the stroke. An increase in circling behavior also appeared at 14 days after the insult. In addition to alterations in DAT, Mortensen *et al.* (2018) analyzed the 5-HT transporter (*SERT*) gene for its role in the relationship between platelet aggregation and ischemia. *SERT* provides the mechanism by which platelets uptake 5-HT, and it has been implicated in myocardial ischemia (Coto *et al.*, 2003); the study of Mortensen *et al.* (2018) revealed that polymorphism-associated genotypes of the *SERT* gene (a high expression *SERT* genotype) may be associated with a reduced risk of cerebral ischemia.

The expression of NE receptors in stroke patients has also provided insight into the progression of stroke pathology and potential treatment. A study by Tsukahara *et al.* (1988) first characterized the role and expression of the  $\alpha$ -adrenergic receptor in subarachnoid-hemorrhage stroke patients using radioligand-binding assays. These seminal findings revealed a reduction of high-affinity  $\alpha$ -adrenergic receptors in the stroke group that was likely caused by sympathetic denervation of NE-containing neurons upon hemorrhagic insult. Furthermore, this denervation was responsible for the increase of NE levels in cerebral arteries and likely contributed to the physiological secondary stroke process of vasospasm, or a spasm of cerebral arteries leading to vasoconstriction and neuronal death in the acute poststroke phase.

Immune-response signaling cascades after stroke have also been shown to impact cognitive ability (Doyle *et al.*, 2015; Becker *et al.*, 2016). It has been recently shown that the converging interaction between the monoaminergic and immune systems after cerebral insult plays an important role in both infarct evolution and the development of therapeutic intervention. This interaction was elucidated in a study by Huck *et al.* (2015), in which the authors showed modulation of the immune response through DA receptor signaling after stroke. In the study, a mouse stroke model was used to quantify DA receptor expression in stroke animals relative to controls. Interestingly, the authors noted *de novo* expression of the DA receptor, D2, on activated microglia in both the infarct and penumbra regions of the mouse brain, in the stroke group relative to the control group. The high expression of D2 receptors was additionally identified in the peripheral macrophages of the stroke animals. This crucial finding suggests a possible role for therapeutic targeting of DAergic receptors as immune modulators in stroke patients.

### Degradation enzymes and metabolites

Degradation enzymes are key in the maintenance of monoaminergic metabolism and homeostasis. Indeed, alterations in monoaminergic degradation enzymes have also been implicated in stroke secondary pathology. The degradation enzyme, catechol-*O*-methyltransferase (COMT), is crucial for maintenance of both DA and NE

metabolism in the brain (Huotari *et al.*, 2002; Kaenmaki *et al.*, 2010). A study by Kim *et al.* (2016) examined the relationship between *COMT* gene polymorphisms and stroke functional recovery. They found that *COMT*-specific polymorphisms were associated with an ability to predict motor recovery in stroke patients in a time-dependent manner. In addition, monoamine oxidases, degradation enzymes located within the mitochondrial cell walls of presynaptic neurons that are responsible for the breakdown of 5-HT, DA, and NE into their respective metabolites, 5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylacetic acid, homovanillic acid, 3-methoxytyramine, 3,4-dihydroxymandelic acid, and 3-methoxy-4-hydroxyphenylglycol, are also implicated in poststroke outcomes. As such, studies have evaluated the isolation of these monoaminergic metabolites after stroke and found increased concentrations in CSF using high-performance liquid chromatography (Wester *et al.*, 1987; Tang *et al.*, 1989). Additional work by Uzbekov *et al.* (2011) analyzed blood samples from ischemic stroke patients and found increased monoamine oxidases activity in stroke platelet samples several days after the initial ischemic insult. They suggested that this effect could be a compensatory mechanism to re-establish brain tissue homeostasis, as an increase in stroke monoamine activity is likely due to an increase in monoamine deamination activation and subsequent glutamate-induced excitotoxicity.

## **Behavioral sequela secondary to stroke-related executive dysfunction**

### **Poststroke depression**

PSD affects at least one-third of stroke patients (Santos *et al.*, 2009) and has become of crucial importance within the biomedical field. Symptomatically, patients with PSD often present with many of the same afflictions as patients with major depressive disorder, in particular, executive-function impairment. Moreover, the relevance of PSD to executive function has been thoroughly studied (Pohjasvaara *et al.*, 2002; Nunes *et al.*, 2012; Sobreiro *et al.*, 2014; Nilsson *et al.*, 2016) and, at present, has far-reaching implications for public health (Amaricai and Poenaru, 2016). Indeed, commonly impacted components of executive function among PSD individuals are working memory and specific components of cognitive flexibility, such as attentional control (Pohjasvaara *et al.*, 2002; Nunes *et al.*, 2012; Nilsson *et al.*, 2016). A prospective study by Ilut *et al.* (2017) examined potential factors that could influence the severity of PSD. Both stroke-lesion location and the number of lesions were associated with severity levels of PSD, with patients diagnosed with left hemisphere and/or basal nuclei-located or frontal lobe-located lesions suffering from significantly more severe PSD, and patients with a smaller number of lesions (e.g. 1–2) being more likely to develop mild-to-moderate PSD than patients with a great number of lesions (e.g. 3–4). As well, Sibolt *et al.* (2013)

showed that PSD is more likely to occur in patients with recurring stroke episodes. Moreover, as with major depressive disorder, women are more likely to develop PSD than men (Appelros *et al.*, 2010).

It is known that dysregulation of monoaminergic neurotransmitter systems plays a role in PSD. As such, it has been hypothesized that the monoamine theory, in part, characterizes the biochemical underpinnings of PSD, wherein levels of the key biogenic monoamines involved in executive functioning – 5-HT, DA, and NE – have reduced bioavailability in various regions of the PFC [for reviews, see Loubinoux *et al.* (2012); Feng *et al.* (2014)]. Evidence to support the monoamine theory of PSD has been demonstrated in numerous studies. For example, Gao *et al.* (2008) sampled stroke survivors diagnosed with PSD and found that, relative to healthy controls, PSD patients had significantly lower levels of plasma and CSF 5-HT. Further evidence supporting the decrease of 5-HT levels among PSD patients was reported in a study by Ramasubbu *et al.* (2008), which examined the genetic make-up of stroke patients with PSD, and found a relationship between a single nucleotide polymorphism encoding for an SERT gene and an increased risk for developing PSD after stroke. Specifically, Ramasubbu *et al.* (2008) implemented polymerase chain reaction genotyping to analyze a specific promoter region of the SERT gene, 5-HTTLPR/rs25531, among PSD and healthy controls, and found that PSD patients had lower-occurring allelic frequencies of the SERT gene-promoter region relative to healthy individuals.

In addition to 5-HTergic system dysregulation, alterations of NE and DA neurotransmitter systems have also been implicated in PSD. For example, Ji *et al.* (2014) utilized high-performance liquid chromatography to assess levels of 5-HT, NE, and DA in the PFC and hippocampus of a rat model of PSD. Levels of all three neurotransmitters were significantly diminished in the PSD group relative to the stroke group. The importance of DAergic neurotransmission in poststroke affective behavior has also been elucidated in a human study by Delbari *et al.* (2011). Stroke patients were prospectively enrolled in the study during which they were administered the biochemical precursor of DA, levodopa, and the DA reuptake inhibitor, methylphenidate, in combination with physiotherapy during the acute recovery phase after stroke. Results showed significant improvements in mood and cognition in the levodopa + methylphenidate group relative to a placebo control group, as measured by various mood, cognitive, and neurological assessments, with the most prominent effects observed in early follow-up timepoints after pharmacological intervention. Moreover, disruption of biogenic monoamine neurotransmission in PSD can be correlated to behavioral changes in animal models. Specifically, Wu *et al.* (2015) showed increased immobility in the forced swim test, decreased mobility in the open field test, and decreased



sucrose consumption in the sucrose preference test in a rat model of PSD, which are all indices of enhanced anxiety-like and depressive-like phenotypes in rodents.

### Drug-abuse potential and addiction

Although the literature supporting the topic is scant, one can hypothesize that, as the size of the stroke populations continue to grow and additional data are acquired, the possibility of poststroke addiction could become a new reality. Currently, it is well established that particular components of executive function, such as impulsivity and decision making, are compromised in individuals suffering from addiction [see review by Bickel *et al.* (2012)]. Furthermore, much is already known about monoaminergic system disruption in addiction. Implications of DA in addiction have been well established (Groman and Jentsch, 2012). 5-HTergic signaling in the medial PFC and OFC has also been implicated in drug-abuse potential, indicated by significant effects of the 5-HT<sub>1A</sub> receptor agonist, 8-OH-DPAT, in decreasing impulsive behavior on a delay-discounting task (London *et al.*, 2000; Schoenbaum and Shaham, 2008; Yates *et al.*, 2014). Moreover, these behavioral deficits are demonstrated in the human stroke population: patients with stroke lesions in the ventral medial PFC opt for immediate gains over future, higher losses in a card gambling task. Further, their card choosing strategies showed poor decision-making abilities and enhanced risk-taking behavior, which indicates a lack of awareness of future consequences (Bechara *et al.*, 2000b). With an already established link between stroke and drug abuse (de los Ríos la Rosa *et al.*, 2012; Fonseca and Ferro, 2013), in which addiction is a known risk factor for stroke, more research is needed to determine whether there is a similar relationship with addiction development after stroke. Indeed, epidemiological studies have indicated that the average age of stroke is decreasing, concomitant with an increased prevalence of stroke in younger populations (Kissela *et al.*, 2012; Smajlovic, 2015), conferring an increase in medical and financial burdens associated with executive function-related impairments in the younger population.

Given the overlap of executive dysfunction-related behavior, monoamine-signaling disruption, and addiction among the adult stroke population, perhaps one overlooked population that could become susceptible to poststroke executive function deficits that could drive subsequent drug-seeking behavior and addiction is that of neonatal and pediatric hypoxic-ischemic insult patients. Specifically, it is well known that hypoxic-ischemic encephalopathy (HIE) is a debilitating condition whereby global ischemic insult due to oxygen deprivation before, during, or shortly after birth can impart devastating behavioral and motor deficits long withstanding into adulthood (Douglas-Escobar and Weiss, 2015; Riljak *et al.*, 2016). Although acknowledged as a diagnosis dissociable from

adult stroke, it is understood that there is substantial pathophysiological parallel between HIE and stroke, as many of the same proinflammatory cascades and monoaminergic systems are altered within both forms of ischemic brain injury (Wurtman and Zervas, 1974; Shiraishi *et al.*, 2008; Hama *et al.*, 2017; Povroznik *et al.*, 2018). Of these stroke and HIE-related deficits, and relevant to the present review, executive function profiles of children with HIE have been examined. A study by Hayes *et al.*, (2018) found that, of the components of executive function assessed using the Behavior Rating Inventory of Executive Function, children less than 42 months of age who were diagnosed with HIE at birth showed attention-related and working memory-related deficits relative to healthy controls. These findings can be correlated to a previous study by Decker *et al.* (2003), in which DA neurotransmission was disrupted in neonatal HIE rat pups, as it is known that dopaminergic signaling is key to attentional control and working memory function (Nicoullon, 2002; Shiner *et al.*, 2015). Thus, it is possible that children who have experienced neonatal HIE represent an at-risk population for developing addiction later in life, a burden they will carry for many decades. That the literature specifically examining this issue is scant warrants more research in this component.

### Pharmacological considerations for stroke in the context of executive function

In light of the fact that tissue plasminogen activator, aimed primarily at recanalization, is currently the only FDA-approved therapeutic intervention for ischemic stroke (Rouchaud *et al.*, 2011; Mozaffarian *et al.*, 2015), there is a crucial clinical need to develop additional interventions that can address the spectrum of long-term pathological consequences of stroke, including disruptions to executive function. Targeting the monoaminergic system may be a viable option, as emerging evidence suggests positive impacts on functional recovery, especially in the domain of motoric ability (Chollet *et al.*, 2014; Cramer, 2015). Indeed, beneficial findings of the FLAME trial, in which a selective 5-HT reuptake inhibitor (SSRI), fluoxetine, improved motor recovery among nondepressed stroke patients, indicate that monoamine-targeted treatments could represent a promising new intervention (Chollet *et al.*, 2011). This is supported by collective findings of the recent Cochrane meta-analysis noting benefits primarily in motor and affective domains (Mead *et al.*, 2013) as well as other small clinical trials in which other drugs targeting 5-HT were used to induce positive effects on poststroke motor performance (Zittel *et al.*, 2008; Acler *et al.*, 2009).

Similar beneficial impacts on poststroke outcomes have been reported with other monoamine-targeted treatments. For example, physical therapy combined with L-DOPA treatment in poststroke patients was associated with significantly greater motor improvement, as compared with

placebo treatment, an effect that persisted at least 3 weeks following the cessation of treatment (Scheidtmann *et al.*, 2001). The results of the multicenter, randomized, double-blinded, placebo-controlled Dopamine Augmented Rehabilitation in Stroke clinical trial (Bhakta *et al.*, 2014), in which the L-DOPA medication, co-careldopa, will be evaluated for its potential to improve motor recovery, are eagerly anticipated. Administration of other DA agonists has yielded beneficial impacts on functional recovery, improved somatosensory circuit remodeling, attention, and mood (Sami and Faruqui, 2015; Obi *et al.*, 2018).

Although a paucity of studies evaluating the impacts of noradrenergic modulation have been conducted to date, evidence is promising. Indeed, stroke patients treated with dextroamphetamine, a potent NE stimulator, showed improved motor recovery when paired with physical therapy, as compared with placebo-treated patients [Walker-Batson *et al.*, 1995; but see Sprigg and Bath (2009), for review of the accumulating evidence to suggest that amphetamines impair stroke recovery]. In a pilot study, acute inhibition of the NE transporter with reboxetine resulted in improved motor recovery and partially restored neural circuit connectivity following stroke in human patients (Zittel *et al.*, 2007; Wang *et al.*, 2011). It has been hypothesized that targeting these systems induces benefits in the ischemic brain by their ability to modulate inhibitory signaling pathways, enhance long-term potentiation, facilitate neurogenesis, and promote neural plasticity [reviewed by Feeney *et al.* (2004); Chollet *et al.* (2014); Cramer (2015); Siepmann *et al.* (2015); Pinto *et al.* (2017)].

Whether monoamine-targeted therapies will exert beneficial effects for domains of cognition and executive function in addition to locomotor ability remains to be thoroughly evaluated. Findings pointing to the monoaminergic system as a new therapeutic target for stroke are encouraging; however, not all studies have reported positive results. For example, the Cochrane meta-analysis noted no benefit of SSRI treatment in cognitive domains, in which executive function is grouped, and the FLAME trial did not evaluate cognition at all (Chollet *et al.*, 2011; Mead *et al.*, 2013). Further, while several studies noted benefits of SSRI treatment after ischemic stroke on motor recovery, prestroke or peristroke SSRI use was associated with increased hemorrhagic stroke severity and mortality (Miedema *et al.*, 2010; Mortensen *et al.*, 2014), highlighting the potential for stroke etiology and/or premorbid conditions such as depression to interact with the actions of SSRIs in the context of acute brain injury. Similarly, treatment with DAergic system modulators such as the D2, D3 and D4 agonist, ropinirole, has not always shown beneficial effects (Cramer *et al.*, 2009). This may be due to a receptor-specific effect, as Okada *et al.* (2005) reported that antagonism of the D4 receptor attenuated stroke-induced cell damage *in vitro*. Finally, while others have

shown that reductions in NE were associated with worse functional recovery (Beltran *et al.*, 2010), Windle *et al.* (2007) noted beneficial effects of NE depletion on a variety of rodent tests of motoric ability. These collective findings suggest that the relationship between poststroke recovery and monoaminergic-system modulation may be more complex than previously appreciated, presenting additional challenges in translating findings from rodents to humans, and implementing these interventions in the clinic, especially in the context of executive dysfunction. Future interventions may need to consider the targeting of multiple neurotransmitters and/or multiple levels of the monoaminergic systems.

More broadly, the current lack of viable neurorestorative interventions for stroke and the null or negative findings of recent clinical trials evaluating efficacy of novel interventions is disheartening and has warranted careful scrutiny among scientists and clinicians of the causes for these failures. One cause may relate to stroke injury-induced changes in the actions of drugs in the body following cerebral ischemia (Alavijeh *et al.*, 2005; Conrado *et al.*, 2010). Indeed, one report noted that ~40% of the failed clinical trials of new drugs from a group of UK pharmaceutical companies occurred as a result of pharmacokinetic-related issues (Prentis *et al.*, 1988). Further, the lack of efficacy of many neuroprotective drugs developed for stroke that failed clinical trials were shown to have very low therapeutic ratios when tested in rodents, calculated as the ratio between the minimum effective dose for rotarod impairment and that for significant neuroprotection from ischemic infarct (Dawson *et al.*, 2001). Following a stroke, alterations of the metabolic pathway of exogenously administered drugs occur at nearly every level, ranging from limitations in ingestion to altered rates of absorption to disrupted enzymatic metabolism (Conrado *et al.*, 2010). This suggests that the timetable of pharmacological actions of drugs, especially orally administered interventions, may be significantly impacted and possibly delayed. Moreover, genetic variants can modulate drug metabolism, therapeutic effectiveness, and treatment-associated risk for adverse events for agents commonly prescribed to stroke patients (Meschia, 2009). Indeed, several genetic factors are known to modulate the response to antiplatelet agents, statins, anticoagulants, and antihypertensive agents, sometimes reducing the beneficial effects these interventions may have on stroke prevention or recovery. Thus, nontypical doses of a given drug may be required to exert the desired effect in the context of ischemic brain injury.

From a research perspective, these issues are problematic, given that the majority of preclinical investigations wherein drug discovery research takes place are conducted using inbred rodent strains, tightly controlled methods for inducing cerebral ischemia, and routes of administration wherein many of these drug metabolism

issues are obviated (Greenhalgh *et al.*, 2011). While these approaches are key to isolating observed beneficial outcomes of an experiment to the intervention of interest, they also limit the translatability of such discoveries. Further, heterogeneous responses to clinical interventions can reduce the ability to detect meaningful pharmacologic action of a novel intervention for the broad stroke-patient population. This can be especially problematic when a drug has a narrow therapeutic margin, and can lead to the presumed failure of the new drug when in reality it may be very effective, but suited for a particular type of stroke and/or subpopulation of stroke patients. Validation of new stroke drugs in outbred strains, as well as continued advances in genetic screening and individualized medicine, will likely improve translation of novel pharmacologic interventions. However, these efforts will be associated with significant expense. Indeed, as the field of molecular genetics is still nascent, genetic screening for drug responsiveness is not currently standard practice, resulting in high costs. Moving forward, these costs must be weighed with the known expenses associated with failed clinical trials.

Timing of drug administration after injury is emerging as a potentially critical component of effective stroke therapy. Cerebral ischemic events induce changes in the permeability of the BBB that may affect drug concentrations at the target tissue (Greenhalgh *et al.*, 2011). Importantly, this opening of the BBB can occur at multiple timepoints following injury and reperfusion, underscoring the importance of accurately pinpointing the time of injury and indicating the potential need to factor time-since-injury in the dosing of any pharmacological intervention administered. The trajectory of BBB permeability after stroke can also be affected by other factors, such as the presence of an active infection associated with the ischemic event (McColl *et al.*, 2008). Such observations suggest that postinjury timepoints for maximal efficacy of a compound should be a consideration for any newly developed neuroprotective agent. For example, pharmacologic recanalization agents should continue to be administered as soon as possible, whereas agents to promote the normalization of the monoaminergic system could be administered at a later timepoint and may still impart their neurorestorative effects. Similarly, dose titration of interventions across the recovery period may be necessary, as stroke-induced disruptions to the gastrointestinal system are attenuated with increasing time since injury (Conrado *et al.*, 2010). Together, these findings highlight a need to reconsider the 'one-size fits all' approach and move towards a more individualized medicine approach for the treatment of ischemic and hemorrhagic stroke, wherein factors such as genetic variants in drug responsiveness, etiology of and time since stroke, and the presence of mitigating/comorbid factors are core features of the treatment decision process.


## Limitations in the field

The expansive range of stroke patients afflicted with executive dysfunction can likely be attributed to, in part, the heterogeneous nature of executive function, the diagnosis of its dysfunction, and its assessment postinjury. Moreover, variation among animal stroke models may influence the types of executive function domains affected. Perhaps the most prominent issue arises when trying to define executive function; although technical definitions have been established, there is still significant overlap among the behavioral phenotypes, neuroanatomical pathways, and neurotransmitter systems underlying the various components of executive function, especially when considering how many of these processes are inherently interdependent upon one another. This overlap makes it difficult to therapeutically target the cellular and molecular substrates that control specific components of executive function accurately. Compounding this is considerable heterogeneity in the diagnosis and assessment of executive dysfunction, as clinicians and preclinical researchers implement a variety of neurological scales and cognitive assessments used to test behavioral phenotypes of specific components and/or multiple components simultaneously, thus increasing the difficulty in deducing the differences between individual components. These limitations, combined with variation in animal model-induced physiologic and behavioral outcomes, generate less than optimal translational validity. As such, increased optimization and standardization of animal stroke models and executive function diagnostic and assessment tools could improve upon these issues.

## Conclusion and future directions

In summary, the devastating impacts of stroke and its secondary consequences are well known, and, with increasing prevalence, require much attention from clinicians and basic scientists. Of the secondary consequences, impairment of executive function is a heterogeneous syndrome in which the simultaneous interplay of multiple cognitive processes that comprise one's ability to reason and solve problems is often severely compromised. This impairment can prove detrimental to quality of life in stroke patients, as the components of executive function are necessary tenets of real-world functioning. Associated with these behavioral detriments, is known monoaminergic dysregulation following stroke, particularly within the DAergic, NEergic, and 5-HTergic systems. Variation within monoamine disruption is inherent, as impairment can happen at various stages during the neurotransmitter life cycle. However, to date, limited literature exists examining interactions between stroke, monoamine disruption, and executive dysfunction. This knowledge gap is likely complicated by various parameters, such as age, sex, severity of infarct, location and size of the lesion, post-stroke timepoint during which monoamine systems and executive functions are assessed following stroke (i.e.

Fig. 1



(a) Current knowledge of monoamine dysregulation and executive function impairment following stroke. A review of the literature reveals studies that address the following relationships: (i) monoamine neurotransmission (in particular, NE, DA, and 5-HT) disruption following stroke, (ii) executive dysfunction associated with various models of stroke, and (iii) monoamine neurotransmission modulation during executive function/dysfunction. Yet, currently, scant literature exists examining interactions between all three factors concurrently, and the literature that does exist can be conflicting. This knowledge gap is likely complicated by various parameters that modulate stroke outcome, monoaminergic neurotransmission disruption, and executive function impairment, as well as, the potential for disruption of multiple stages of monoaminergic neurotransmission (synthesis, distribution, reuptake, and degradation). (b) Proposed model of stroke-induced executive dysfunction. Given the known relationships between monoamine neurotransmission and executive function disruption after stroke, in addition to well-established literature showing changes in executive function following manipulation of one or more monoaminergic neurotransmitter systems, it is possible that a linear relationship in which stroke leads to executive dysfunction by changes in monoamine systems exists. Thus one or a combination of monoaminergic neurotransmitters and/or multiple levels of monoamine regulation may prove as viable therapeutic targets to ameliorate the spectrum of stroke-induced executive function deficits that may be realized. DA, dopamine; 5-HT, serotonin; NE, norepinephrine.

acute vs. chronic assessments), and stroke-induced changes in the pharmacology of therapeutic interventions. Thus, given the known relationships between stroke, monoamine systems, and executive function (Fig. 1a), one may postulate that the factors comprise a linear relationship, wherein monoamine system modulation following stroke leads to executive function deficits (Fig. 1b). Moving forward, therapeutic intervention which targets not only one, but, perhaps, a combination of different monoamine systems at various levels of

neurotransmitter regulation, may prove successful in ameliorating these stroke-induced deficits. Furthermore, careful consideration should be given when selecting which stroke model to implement, as different models emphasize distinctive structural and functional, brain-related characteristics within the human stroke population, and therefore may impact both different components of executive function and monoaminergic neurotransmission in an unequal manner. Stroke model variation should also be well advised during therapeutic

development, as incommensurately impaired components may require different dosing regimens or perhaps differing therapeutic applicability altogether. As such, additional research to dissociate the different components of executive function impacted by stroke and standardization of assessments to evaluate these individual components, in conjunction with refinement and optimization of current animal stroke models, may enhance clinical translation of experimental research, and is warranted.

## Acknowledgements

This work was supported by NIH funds (WV Stroke CoBRE; NIGMS P20 GM109098, WV CTSI; NIGMS U54 GM104942) and by internal WVU SOM monies, as well as WVU Research Office funds.

## Conflicts of interest

There are no conflicts of interest.

## References

- Accler M, Robol E, Fiaschi A, Manganotti P (2009). A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. *J Neurol* **256**:1152–1158.
- Agarwalla PK, Stapleton CJ, Ogilvy CS (2014). Craniectomy in acute ischemic stroke. *Neurosurgery* **74** (Suppl):S151–S162.
- Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM (2005). Drug metabolism and pharmacokinetics, the blood–brain barrier, and central nervous system drug discovery. *NeuroRx* **2**:554–571.
- Alharbi BM, Tso MK, Macdonald RL (2016). Animal models of spontaneous intracerebral hemorrhage. *Neurol Res* **38**:448–455.
- Amaricai E, Poenaru DV (2016). The post-stroke depression and its impact on functioning in young and adult stroke patients of a rehabilitation unit. *J Ment Health* **25**:137–141.
- Appelros P, Stegmayr B, Terent A (2010). A review on sex differences in stroke treatment and outcome. *Acta Neurol Scand* **121**:359–369.
- Arnsten AF, Li BM (2005). Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. *Biol Psychiatry* **57**:1377–1384.
- Bacigaluppi M, Comi G, Hermann DM (2010). Animal models of ischemic stroke. Part two: modeling cerebral ischemia. *Open Neurol J* **4**:34–38.
- Bechara A, Damasio H, Damasio AR (2000a). Emotion, decision making and the orbitofrontal cortex. *Cereb Cortex* **10**:295–307.
- Bechara A, Tranel D, Damasio H (2000b). Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. *Brain* **123** (Pt 11):2189–2202.
- Becker KJ, Tanzi P, Zierath D, Buckwalter MS (2016). Antibodies to myelin basic protein are associated with cognitive decline after stroke. *J Neuroimmunol* **295**:296–307.
- Beltran EJ, Papadopoulos CM, Tsai SY, Kartje GL, Wolf WA (2010). Long-term motor improvement after stroke is enhanced by short-term treatment with the alpha-2 antagonist, atipamezole. *Brain Res* **1346**:174–182.
- Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2017). Heart disease and stroke statistics-2017 update: a report from the American Heart Association. *Circulation* **135**:e146–e603.
- Bhakta BB, Hartley S, Holloway I, Couzens JA, Ford GA, Meads D, et al. (2014). The DARS (Dopamine Augmented Rehabilitation in Stroke) trial: protocol for a randomised controlled trial of Co-careldopa treatment in addition to routine NHS occupational and physical therapy after stroke. *Trials* **15**:316.
- Bickel WK, Jarmolowicz DP, Mueller ET, Gatchalian KM, McClure SM (2012). Are executive function and impulsivity antipodes? a conceptual reconstruction with special reference to addiction. *Psychopharmacology (Berl)* **221**:361–387.
- Binder LM (1984). Emotional problems after stroke. *Stroke* **15**:174–177.
- Bramlett HM, Dietrich WD (2004). Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. *J Cereb Blood Flow Metab* **24**:133–150.
- Brouns R, van Hemelrijck A, Drinkenburg WH, van Dam D, De Surgeloose D, De Deyn PP (2010). Excitatory amino acids and monoaminergic neurotransmitters in cerebrospinal fluid of acute ischemic stroke patients. *Neurochem Int* **56**:865–870.
- Buelow MT, Suhr JA (2009). Construct validity of the Iowa Gambling Task. *Neuropsychol Rev* **19**:102–114.
- Cai B, Wang N (2016). Large animal stroke models vs. rodent stroke models, pros and cons, and combination? In: Applegate R, Chen G, Feng H, Zhang J, editors. *Brain Edema XVI*. Acta Neurochirurgica Supplement, Vol 121. Springer, Cham.
- Campbell HL, Tivarus ME, Hillier A, Beversdorf DQ (2008). Increased task difficulty results in greater impact of noradrenergic modulation of cognitive flexibility. *Pharmacol Biochem Behav* **88**:222–229.
- Cardoso CDO, Branco LD, Cotrena C, Kristensen CH, Bakos DDGS, Fonseca RP (2014). The impact of frontal and cerebellar lesions on decision making: evidence from the Iowa Gambling Task. *Front Neurosci* **8**:61.
- Cechetti F, Worm PV, Pereira LO, Siqueira IR, Netto CA (2010). The modified 2VO ischemia protocol causes cognitive impairment similar to that induced by the standard method, but with a better survival rate. *Braz J Med Biol Res* **43**:1178–1183.
- Chamberlain SR, Sahakian BJ (2007). The neuropsychiatry of impulsivity. *Curr Opin Psychiatry* **20**:255–261.
- Chan RC, Shum D, Touloupoulou T, Chen EY (2008). Assessment of executive functions: review of instruments and identification of critical issues. *Arch Clin Neuropsychol* **23**:201–216.
- Chen Y, Zhu W, Zhang W, Libal N, Murphy SJ, Offner H, Alkayed NJ (2015). A novel mouse model of thromboembolic stroke. *J Neurosci Methods* **256**:203–211.
- Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *Lancet Neurol* **10**:123–130.
- Chollet F, Tardy J, Albucher JF, Raposo N, Acket B, Sattler V, et al. (2014). Monoaminergic drugs for motor recovery after ischemic stroke. *Ann Phys Rehabil Med* **57**:509–519.
- Cipolotti L, Healy C, Chan E, MacPherson SE, White M, Woollett K, et al. (2015). The effect of age on cognitive performance of frontal patients. *Neuropsychologia* **75**:233–241.
- Conrado DJ, Gonzalez D, Derendorf H (2010). Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke. *Ann N Y Acad Sci* **1207**:134–142.
- Cook DJ, Tymianski M (2012). Nonhuman primate models of stroke for translational neuroprotection research. *Neurotherapeutics* **9**:371–379.
- Cordova CA, Jackson D, Langdon KD, Hewlett KA, Corbett D (2014). Impaired executive function following ischemic stroke in the rat medial prefrontal cortex. *Behav Brain Res* **258**:106–111.
- Coto E, Reguero JR, Alvarez V, Morales B, Batalla A, Gonzalez P, et al. (2003). 5-Hydroxytryptamine 5-HT<sub>2A</sub> receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. *Clin Sci (Lond)* **104**:241–245.
- Crack PJ, Taylor JM (2005). Reactive oxygen species and the modulation of stroke. *Free Radic Biol Med* **38**:1433–1444.
- Cramer SC (2015). Drugs to enhance motor recovery after stroke. *Stroke* **46**:2998–3005.
- Cramer SC, Dobkin BH, Noser EA, Rodriguez RW, Enney LA (2009). Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. *Stroke* **40**:3034–3038.
- Dajani RJ, Uddin LQ (2015). Demystifying cognitive flexibility: implications for clinical and developmental neuroscience. *Trends Neurosci* **38**:571–578.
- Dawson DA, Wadsworth G, Palmer AM (2001). A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. *Brain Res* **892**:344–350.
- De los Rios la Rosa F, Kleindorfer DO, Khoury J, Broderick JP, Moomaw CJ, Adeoye O, et al. (2012). Trends in substance abuse preceding stroke among young adults: a population-based study. *Stroke* **43**:3179–3183.
- Decker MJ, Hue GE, Caudle WM, Miller GW, Keating GL, Rye DB (2003). Episodic neonatal hypoxia evokes executive dysfunction and regionally specific alterations in markers of dopamine signaling. *Neuroscience* **117**:417–425.
- Delbari A, Salman-Roghani R, Lolk J (2011). Effect of methylphenidate and/or levodopa combined with physiotherapy on mood and cognition after stroke: a randomized, double-blind, placebo-controlled trial. *Eur Neurol* **66**:7–13.
- Diamond A (2013). Executive functions. *Annu Rev Psychol* **64**:135–168.
- Dix SL, Aggleton JP (1999). Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition. *Behav Brain Res* **99**:191–200.
- Douglas-Escobar M, Weiss MD (2015). Hypoxic-ischemic encephalopathy: a review for the clinician. *JAMA Pediatr* **169**:397–403.
- Doyle KP, Quach LN, Sole M, Axtell RC, Nguyen TV, Soler-Llavina GJ, et al. (2015). B-lymphocyte-mediated delayed cognitive impairment following stroke. *J Neurosci* **35**:2133–2145.

- ElAli A, Doeppner TR, Zechariah A, Hermann DM (2011). Increased blood-brain barrier permeability and brain edema after focal cerebral ischemia induced by hyperlipidemia: role of lipid peroxidation and calpain-1/2, matrix metalloproteinase-2/9, and RhoA overactivation. *Stroke* **42**:3238–3244.
- Engel O, Kolodziej S, Dirnagl U, Prinz V (2011). Modeling stroke in mice - middle cerebral artery occlusion with the filament model. *J Vis Exp* **47**:1–5.
- Fan J, Li Y, Fu X, Li L, Hao X, Li S (2017). Nonhuman primate models of focal cerebral ischemia. *Neural Regen Res* **12**:321–328.
- Feeney DM, De Smet AM, Rai S (2004). Noradrenergic modulation of hemiplegia: facilitation and maintenance of recovery. *Restor Neurol Neurosci* **22**:175–190.
- Feng C, Fang M, Liu XY (2014). The neurobiological pathogenesis of poststroke depression. *ScientificWorldJournal* **2014**:521349.
- Fonseca AC, Ferro JM (2013). Drug abuse and stroke. *Curr Neurol Neurosci Rep* **13**:325.
- Gao H, Liu Y, Lu S, Xiang B, Wang C (2006). A reversible middle cerebral artery occlusion model using intraluminal balloon technique in monkeys. *J Stroke Cerebrovasc Dis* **15**:202–208.
- Gao HQ, Zhu HY, Zhang YQ, Wang LX (2008). Reduction of cerebrospinal fluid and plasma serotonin in patients with post-stroke depression: a preliminary report. *Clin Invest Med* **31**:E351–E356.
- Gomez P, Ratcliff R, Perea M (2007). A model of the go/no-go task. *J Exp Psychol Gen* **136**:389–413.
- Greenhalgh AD, Ogungbenro K, Rothwell NJ, Galea JP (2011). Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke. *Expert Opin Drug Metab Toxicol* **7**:681–695.
- Groman SM, Jentsch JD (2012). Cognitive control and the dopamine D(2)-like receptor: a dimensional understanding of addiction. *Depress Anxiety* **29**:295–306.
- Gurman P, Miranda OR, Nathan A, Washington C, Rosen Y, Elman NM (2015). Recombinant tissue plasminogen activators (rtPA): a review. *Clin Pharmacol Ther* **97**:274–285.
- Hama S, Murakami T, Yamashita H, Onoda K, Yamawaki S, Kurisu K (2017). Neuroanatomic pathways associated with monoaminergic dysregulation after stroke. *Int J Geriatr Psychiatry* **32**:633–642.
- Hayes BC, Doherty E, Grehan A, Madigan C, McGarvey C, Mulvany S, *et al.* (2008). Neurodevelopmental outcome in survivors of hypoxic ischemic encephalopathy without cerebral palsy. *Eur J Pediatr* **177**:19–32.
- Heidenreich PA, Trogon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, *et al.* (2011). Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. *Circulation* **123**:933–944.
- Howells DW, Porritt MJ, Rewell SSJ, O'Collins V, Sena ES, van Der Worp HB, *et al.* (2010). Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. *J Cereb Blood Flow Metab* **30**:1412–1431.
- Huang P, Chen CH, Yang YH, Lin RT, Lin FC, Liu CK (2006). Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor. *Cerebrovasc Dis* **22**:423–428.
- Huck JH, Freyer D, Bottcher C, Mladinov M, Muselmann-Genschow C, Thielke M, *et al.* (2015). De novo expression of dopamine D2 receptors on microglia after stroke. *J Cereb Blood Flow Metab* **35**:1804–1811.
- Huh Y, Jung JW, Park K, Ryu JR, Shin CY, Kim WK, Ryu JH (2003). Microglial activation and tyrosine hydroxylase immunoreactivity in the substantia nigral region following transient focal ischemia in rats. *Neurosci Lett* **349**:63–67.
- Huotari M, Gogos JA, Karayiorgou M, Koponen O, Forsberg M, Raasmaja A, *et al.* (2002). Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. *Eur J Neurosci* **15**:246–256.
- Ilut S, Blesneag A SA, Vacaras V, Vesa S, Fodoreanu L (2017). Factors that influence the severity of post-stroke depression. *J Med Life* **10**:3.
- Ionescu T (2012). Exploring the nature of cognitive flexibility. *New Ideas Psychol* **30**:190–200.
- James AS, Groman SM, Seu E, Jorgensen M, Fairbanks LA, Jentsch JD (2007). Dimensions of impulsivity are associated with poor spatial working memory performance in monkeys. *J Neurosci* **27**:14358–14364.
- Jensen AR, Rohwer WD Jr (1966). The Stroop color-word test: a review. *Acta Psychol (Amst)* **25**:36–93.
- Ji XW, Wu CL, Wang CL, Liu J, Bi JZ, Wang DY (2014). Monoamine neurotransmitters and fibroblast growth factor-2 in the brains of rats with post-stroke depression. *Exp Ther Med* **8**:159–164.
- Jickling GC, Sharp FR (2015). Improving the translation of animal ischemic stroke studies to humans. *Metab Brain Dis* **30**:461–467.
- Jodzio K, Biechowska D (2010). Wisconsin card sorting test as a measure of executive function impairments in stroke patients. *Appl Neuropsychol* **17**:267–277.
- Jurado MB, Rosselli M (2007). The elusive nature of executive functions: a review of our current understanding. *Neuropsychol Rev* **17**:213–233.
- Kaenmaki M, Tammimaki A, Myohanen T, Pakarinen K, Amberg C, Karayiorgou M, *et al.* (2010). Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. *J Neurochem* **114**:1745–1755.
- Kanda T, Gotoh F, Yamamoto M, Sakai F, Takeoka T, Takagi Y (1979). Serum dopamine-beta-hydroxylase activity in acute stroke. *Stroke* **10**:168–173.
- Kanthan R, Shuaib A, Griebel R, el-Alazouni H, Miyashita H, Kalra J (1996). Evaluation of monoaminergic neurotransmitters in the acute focal ischemic human brain model by intracerebral in vivo microdialysis. *Neurochem Res* **21**:563–566.
- Kaufman S, Friedman S (1965). Dopamine-beta-hydroxylase. *Pharmacol Rev* **17**:71–100.
- Kawai K, Nitecka L, Ruetzler CA, Nagashima G, Joo F, Mies G, *et al.* (1991). Global Cerebral ischemia associated with cardiac arrest in the rat. 1. Dynamics of early neuronal changes. *J Cereb Blood Flow Metab* **12**:238–249.
- Kim BR, Kim HY, Chun YI, Yun YM, Kim H, Choi DH, Lee J (2016). Association between genetic variation in the dopamine system and motor recovery after stroke. *Restor Neurol Neurosci* **34**:925–934.
- Kissela BM, Khoury JC, Alwell K, Moomaw CJ, Woo D, Adeoye O, *et al.* (2012). Age at stroke temporal trends in stroke incidence in a large, biracial population. *Neurology* **79**:1781–1787.
- Kooijman E, Nijboer CH, van Velthoven CTJ, Kavelaars A, Kesecioglu J, Heijnen CJ (2014). The rodent endovascular puncture model of subarachnoid hemorrhage: mechanisms of brain damage and therapeutic strategies. *J Neuroinflammation* **11**:1–12.
- Lesniak M, Bak T, Czepiel W, Seniow J, Czlonkowska A (2008). Frequency and prognostic value of cognitive disorders in stroke patients. *Dement Geriatr Cogn Disord* **26**:356–363.
- Levy R, Goldman-Rakic PS (2000). Segregation of working memory functions within the dorsolateral prefrontal cortex. *Exp Brain Res* **133**:23–32.
- Logue SF, Gould TJ (2014). The neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibition. *Pharmacol Biochem Behav* **123**:45–54.
- London ED, Ernst M, Grant S, Bonson K, Weinstein A (2000). Orbitofrontal cortex and human drug abuse: functional imaging. *Cereb Cortex* **10**:334–342.
- Longa EZ, Weinstein PR, Carlson S, Cummins R (1989). Reversible middle cerebral artery occlusion without craniectomy in rats. *Stroke* **20**:84–91.
- Loubinoux I, Kronenberg G, Endres M, Schumann-Bard P, Freret T, Filipkowski RK, *et al.* (2012). Post-stroke depression: mechanisms, translation and therapy. *J Cell Mol Med* **16**:1961–1969.
- MacLellan CL, Silasi G, Auriat AM, Colbourne F (2010). Rodent models of intracerebral hemorrhage. *Stroke* **41** (Suppl 1):95–99.
- Marbacher S (2016). Animal models for the study of subarachnoid hemorrhage: are we moving towards increased standardization? *Transl Stroke Res* **7**:1–2.
- McColl BW, Rothwell NJ, Allan SM (2008). Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. *J Neurosci* **28**:9451–9462.
- Mead GE, Hsieh CF, Hackett M (2013). Selective serotonin reuptake inhibitors for stroke recovery. *JAMA* **310**:1066–1067.
- Merali Z, Huang K, Mikulis D, Silver F, Kassner A (2017). Evolution of blood-brain-barrier permeability after acute ischemic stroke. *PLoS One* **12**:e0171558.
- Meschia JF (2009). Pharmacogenetics and stroke. *Stroke* **40**:3641–3645.
- Mestas J, Hughes CCW (2004). Of mice and not men: differences between mouse and human immunology. *J Immunol* **172**:2731–2738.
- Miedema I, Horvath KM, Uyttenboogaart M, Koopman K, Lahr MM, De Keyser J, Luijckx GJ (2010). Effect of selective serotonin re-uptake inhibitors (SSRIs) on functional outcome in patients with acute ischemic stroke treated with tPA. *J Neurol Sci* **293**:65–67.
- Momomaki S, Ito M, Yamato H, Iimori H, Sumiyoshi H, Morimoto K, *et al.* (2016). Longitudinal imaging of the availability of dopamine transporter and D2 receptor in rat striatum following mild ischemia. *J Cereb Blood Flow Metab* **37**:605–613.
- Mori K (2014). Double cisterna magna blood injection model of experimental subarachnoid hemorrhage in dogs. *Transl Stroke Res* **5**:647–652.
- Mortensen JK, Larsson H, Johnsen SP, Andersen G (2014). Impact of prestroke selective serotonin reuptake inhibitor treatment on stroke severity and mortality. *Stroke* **45**:2121–2123.
- Mortensen JK, Kraglund KL, Johnsen SP, Mors O, Andersen G, Buttenschon HN (2018). The serotonin transporter gene polymorphisms and risk of ischemic stroke. *Cerebrovasc Dis* **45**:187–192.
- Mountain MA, Snow WG (1993). Wisconsin card sorting test as a measure of frontal pathology: a review. *Clin Neuropsychol* **7**:108–118.
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, *et al.*, American Heart Association Statistics Committee and Stroke Statistics

- Subcommittee. (2015). Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. *Circulation* **131**:e29–e322.
- Nieoullon A (2002). Dopamine and the regulation of cognition and attention. *Prog Neurobiol* **67**:53–83.
- Nilsson J, Thomas AJ, Stevens LH, McAllister-Williams RH, Ferrier IN, Gallagher P (2016). The interrelationship between attentional and executive deficits in major depressive disorder. *Acta Psychiatr Scand* **134**:73–82.
- Nunes D, Monteiro L, Lopes E (2012). Executive dysfunction in depression: a study of prefrontal dysfunction. *Acta Neuropsychol* **10**:499–508.
- Nyhus E, Barcelo F (2009). The Wisconsin Card Sorting Test and the cognitive assessment of prefrontal executive functions: a critical update. *Brain Cogn* **71**:437–451.
- Obi K, Amano I, Takatsuru Y (2018). Role of dopamine on functional recovery in the contralateral hemisphere after focal stroke in the somatosensory cortex. *Brain Res* **1678**:146–152.
- Okada Y, Sakai H, Kohiki E, Suga E, Yanagisawa Y, Tanaka K, et al. (2005). A dopamine D4 receptor antagonist attenuates ischemia-induced neuronal cell damage via upregulation of neuronal apoptosis inhibitory protein. *J Cereb Blood Flow Metab* **25**:794–806.
- Olmez I, Ozyurt H (2012). Reactive oxygen species and ischemic cerebrovascular disease. *Neurochem Int* **60**:208–212.
- Ormstad H, Verkerk R, Aass HC, Amthor KF, Sandvik L (2013). Inflammation-induced catabolism of tryptophan and tyrosine in acute ischemic stroke. *J Mol Neurosci* **51**:893–902.
- Paterson NE, Wetzler C, Hackett A, Hanania T (2012). Impulsive action and impulsive choice are mediated by distinct neuropharmacological substrates in rat. *Int J Neuropsychopharmacol* **15**:1473–1487.
- Pinto CB, Saleh Velez FG, Lopes F, de Toledo Piza PV, Di Pietro L, Wang QM, et al. (2017). SSRI and motor recovery in stroke: reestablishment of inhibitory neural network tonus. *Front Neurosci* **11**:637.
- Phillips KA, Bales KL, Capitanio JP, Conley A, Czoty PW, 't Hart BA, et al. (2015). Why primate models matter. *Am J Primatol* **76**:801–827.
- Pohjasvaara T, Leskela M, Vataja R, Kalska H, Ylikoski R, Hietanen M, et al. (2002). Post-stroke depression, executive dysfunction and functional outcome. *Eur J Neurol* **9**:269–275.
- Poulin V, Korner-Bitensky N, Dawson DR (2013). Stroke-specific executive function assessment: a literature review of performance-based tools. *Aust Occup Ther J* **60**:3–19.
- Povroznik JM, Engler-Chiurazzi EB, Nanavati T, Pergami P (2018). Absolute lymphocyte and neutrophil counts in neonatal ischemic brain injury. *SAGE Open Med* **6**:2050312117752613.
- Prentis RA, Lis Y, Walker SR (1988). Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985). *Br J Clin Pharmacol* **25**:387–396.
- Ramasubbu R, Tobias R, Bech-Hansen NT (2008). Extended evaluation of serotonin transporter gene functional polymorphisms in subjects with post-stroke depression. *Can J Psychiatry* **53**:197–201.
- Rangel-Castilla L, Rajah GB, Shakir HJ, Davies JM, Snyder KV, Siddiqui AH, et al. (2016). Acute stroke endovascular treatment: tips and tricks. *J Cardiovasc Surg (Torino)* **57**:758–768.
- Riepe MW, Riss S, Bittner D, Huber R (2004). Screening for cognitive impairment in patients with acute stroke. *Dement Geriatr Cogn Disord* **17**:49–53.
- Riljak V, Kraf J, Daryanani A, Jiruska P, Otahal J (2016). Pathophysiology of perinatal hypoxic-ischemic encephalopathy – biomarkers, animal models and treatment perspectives. *Physiol Res*, **65** (Suppl 5):S533–S545.
- Robbins TW, Arnsten AF (2009). The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. *Annu Rev Neurosci* **32**:267–287.
- Roharikova V (2016). Neurobiology of motor impulsivity. *Acta Nerv Super Rediviva* **58**:57–59.
- Rouchaud A, Mazighi M, Labreuche J, Meseguer E, Serfaty JM, Laissy JP, et al. (2011). Outcomes of mechanical endovascular therapy for acute ischemic stroke: a clinical registry study and systematic review. *Stroke* **42**:1289–1294.
- Roussel M, Dujardin K, Henon H, Godefroy O (2012). Is the frontal dysexecutive syndrome due to a working memory deficit? Evidence from patients with stroke. *Brain* **135** (Pt 7):2192–2201.
- Rush RA, Geffen LB (1980). Dopamine beta-hydroxylase in health and disease. *Crit Rev Clin Lab Sci* **12**:241–277.
- Sami MB, Faruqi R (2015). The effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and stroke. *Acta Neuropsychiatry* **27**:317–326.
- Santos M, Kovari E, Gold G, Bozikas VP, Hof PR, Bouras C, Giannakopoulos P (2009). The neuroanatomical model of post-stroke depression: towards a change of focus? *J Neurol Sci* **283**:158–162.
- Scarpina F, Tagini S (2017). The Stroop Color and Word Test. *Front Psychol* **8**:557.
- Scheffer M, Kroeft C, Steigleder BG, Klein LA, Grassi-Oliveira R, de Almeida RMM (2016). Right frontal stroke: extra frontal lesions, executive functioning and impulsive behavior. *Psychol Res Rev* **29**:28.
- Scheidtmann K, Fries W, Muller F, Koenig E (2001). Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. *Lancet* **358**:787–790.
- Schoenbaum G, Shaham Y (2008). The role of orbitofrontal cortex in drug addiction: a review of preclinical studies. *Biol Psychiatry* **15**:1203–1214.
- Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, et al. (2013). Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. *Circ Cardiovasc Qual Outcomes* **6**:543–549.
- Shiner T, Symmonds M, Guitart-Masip M, Fleming SM, Friston KJ, Dolan RJ (2015). Dopamine, salience, and response set shifting in prefrontal cortex. *Cereb Cortex* **25**:3629–3639.
- Shiraishi M, Takizawa Y, Ide S, Obonai T, Goto Y, Itoh M (2008). Brainstem monoamine pathology of neonatal hypoxic-ischemic brain damage: a model of acute stage of neonatal asphyxia. *Brain Res* **1213**:120–126.
- Sibolt G, Curtze S, Melkas S, Pohjasvaara T, Kaste M, Karhunen PJ, et al. (2013). Post-stroke depression and depression-executive dysfunction syndrome are associated with recurrence of ischaemic stroke. *Cerebrovasc Dis* **36**:336–343.
- Siepmann T, Penzlin AI, Kepplinger J, Illigens BM, Weidner K, Reichmann H, Barlann K (2015). Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. *Brain Behav* **5**:e00373.
- Sinar EJ, Mendelow AD, Graham DI, Teasdale GM (1987). Experimental intracerebral hemorrhage: effects of a temporary mass lesion. *J Neurosurg* **66**:568–576.
- Smajlovic D (2015). Strokes in young adults: epidemiology and prevention. *Vasc Health Risk Manag* **11**:157–164.
- Sobriero MFM, Miotto EC, Terroni L, Tinone G, Iosifescu DV, de Lucia MCS, et al. (2014). Executive function and depressive symptoms of retardation in non-elderly stroke patients. *J Clin Exp Neuropsychol* **36**:636–647.
- Soriano MA, Justicia C, Ferrer I, Rodriguez-Farre E, Planas AM (1997). Striatal infarction in the rat causes a transient reduction of tyrosine hydroxylase immunoreactivity in the ipsilateral substantia nigra. *Neurobiol Dis* **4**:376–385.
- Sprigg N, Bath PM (2009). Speeding stroke recovery? a systematic review of amphetamine after stroke. *J Neurol Sci* **285**:3–9.
- Squire B, Bloom DL, Ghosh S (2013). In: Squire L, Berg D, Bloom FE, du Lac S, Ghosh A, Spitzer NC, editors. *Fundamental Neuroscience*, 4th ed. Amsterdam: Elsevier.
- Su CY, Lin YH, Kwan AL, Guo NW (2008). Construct validity of the Wisconsin Card Sorting Test-64 in patients with stroke. *Clin Neuropsychol* **22**:273–287.
- Tajiri N, Dailey T, Metcalf C, Mosley YI, Lau T, Staples M, et al. (2013). In vivo animal stroke models: a rationale for rodent and non-human primate models. *Transl Stroke Res* **4**:308–321.
- Tamura A, Asano T, Sano K, Tsumagari T, Nakajima A (1979). Protection from cerebral ischemia by a new imidazole derivative (Y-9179) and pentobarbital. a comparative study in chronic middle cerebral artery occlusion in cats. *Stroke* **10**:126–134.
- Tang HZ, Lu XF, Wang KJ, Ouyang S, Huang YQ (1989). Monoamine metabolites in cerebrospinal fluid during and after acute cerebral ischemia. *Mol Chem Neuropharmacol* **10**:77–85.
- Traystman RJ (2003). Animal models of focal and global cerebral ischemia. *ILAR J* **44**:85–95.
- Tsukada H, Fukumoto D, Nishiyama S, Sato K, Kakiuchi T (2004). Transient focal ischemia affects the cAMP second messenger system and coupled dopamine D1 and 5-HT1A receptors in the living monkey brain: a positron emission tomography study using microdialysis. *J Cereb Blood Flow Metab* **24**:898–906.
- Tsukahara T, Taniguchi T, Miwa S, Shimohama S, Fujiwara M, Nishikawa M, Handa H (1988). Presynaptic and postsynaptic alpha 2-adrenergic receptors in human cerebral arteries and their alteration after subarachnoid hemorrhage. *Stroke* **19**:80–83.
- Tyson GW, Teasdale GW, Graham DI, McCulloch J (1984). Focal cerebral ischemia in the rat: topography of hemodynamic and histopathological changes. *Ann Neurol* **15**:559–567.
- Uzbekov MG, Alferova VV, Misionzhnik EY, Gekht AB (2011). Change in platelet monoamine oxidase activity in the acutest period of ischemic stroke is associated with the degree of neurological recovery. *Bull Exp Biol Med* **152**:195–197.
- van Geldorp B, Kessels RPC, Hendriks MPH (2013). Single-item and associative working memory in stroke patients. *Behav Neurol* **26**:199–201.
- Verdejo-Garcia A, Clark L, Verdejo-Roman J, Albein-Urios N, Martinez-Gonzalez JM, Gutierrez B, Soriano-Mas C (2015). Neural substrates of

- cognitive flexibility in cocaine and gambling addictions. *Br J Psychiatry* **207**:158–164.
- Virley D, Hadingham SJ, Roberts JC, Farnfield B, Elliott H, Whelan G, et al. (2004). A new primate model of focal stroke: endothelin-1-induced middle cerebral artery occlusion and reperfusion in the common marmoset. *J Cereb Blood Flow Metab* **24**:24–41.
- Vogel-Ciernia A, Wood MA (2014). Examining object location and object recognition memory in mice. *Curr Protoc Neurosci* **69**:8.
- Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R (1995). Amphetamine paired with physical therapy accelerates motor recovery after stroke. *Stroke* **26**:2254–2259.
- Wang LE, Fink GR, Diekhoff S, Rehme AK, Eickhoff SB, Grefkes C (2011). Noradrenergic enhancement improves motor network connectivity in stroke patients. *Ann Neurol* **69**:375–388.
- Wang L, Qin C, Yang G (2017). Animal models for ischemic stroke In: Lapchak P, Yang GY, editors. *Translational Research in Stroke*. Translational Medicine Research. Springer: Singapore. pp. 357–379.
- Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD (1985). Induction of reproducible brain infarction by photochemically initiated thrombosis. *Ann Neurol* **17**:497–504.
- Weinberger J, Nieves-Rosa J (1988). Monoamine neurotransmitters in the evolution of infarction in ischemic striatum: morphologic correlation. *J Neural Transm* **71**:133–142.
- Wells AJ, Vink R, Blumbergs PC, Brophy BP, Helps SC, Knox SJ, Turner RJ (2012). A surgical model of permanent and transient middle cerebral artery stroke in the sheep. *PLoS One* **7**:1–9.
- Wester P, Gottfries J, Johansson K, Klinteback F, Winblad B (1987). Simultaneous liquid chromatographic determination of seventeen of the major monoamine neurotransmitters, precursors and metabolites. I. Optimization of the mobile phase using factorial designs and a computer program to predict chromatograms. *J Chromatogr* **415**:261–274.
- Windle V, Power A, Corbett D (2007). Norepinephrine depletion facilitates recovery of function after focal ischemia in the rat. *Eur J Neurosci* **26**:1822–1831.
- Wu C, Zhang J, Chen Y (2015). Study on the behavioral changes of a post-stroke depression rat model. *Exp Ther Med* **10**:159–163.
- Wurtman RJ, Zervas NT (1974). Monoamine neurotransmitters and the pathophysiology of stroke and central nervous system trauma. *J Neurosurg* **40**:34–36.
- Yan T, Chopp M, Chen J (2015). Experimental animal models and inflammatory cellular changes in cerebral ischemic and hemorrhagic stroke. *Neurosci Bull* **31**:717–734.
- Yang D, Nakajo Y, Iihara K, Kataoka H, Nakagawara J, Zhao Q, Yanamoto H (2014). An integrated stroke model with a consistent penumbra for the assessment of neuroprotective interventions. *Eur Neurol* **71**:4–18.
- Yates JR, Perry JL, Meyer AC, Gipson CD, Charnigo R, Bardo MT (2014). Role of medial prefrontal and orbitofrontal monoamine transporters and receptors in performance in an adjusting delay discounting procedure. *Brain Res* **1574**:26–36.
- Zhou LYY, Wright TE, Clarkson AN (2016). Prefrontal cortex stroke induces delayed impairment in spatial memory. *Behav Brain Res* **296**:373–378.
- Ziemus B, Baumann O, Luerding R, Schlosser R, Schuierer G, Bogdahn U, Greenlee MW (2007). Impaired working-memory after cerebellar infarcts paralleled by changes in BOLD signal of a cortico-cerebellar circuit. *Neuropsychologia* **45**:2016–2024.
- Zinn S, Bosworth HB, Hoenig HM, Swartzwelder HS (2007). Executive function deficits in acute stroke. *Arch Phys Med Rehabil* **88**:173–180.
- Zittel S, Weiller C, Liepert J (2007). Reboxetine improves motor function in chronic stroke. A pilot study. *J Neurol* **254**:197–201.
- Zittel S, Weiller C, Liepert J (2008). Citalopram improves dexterity in chronic stroke patients. *Neurorehabil Neural Repair* **22**:311–314.